It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite the availability of highly sensitive polymerase chain reaction (PCR)-based methods, the dearth of remotely deployable diagnostic tools circumvents the early and accurate detection of individuals with post-kala-azar dermal leishmaniasis (PKDL). Here, we evaluate a design-locked loop-mediated isothermal amplification (LAMP) assay to diagnose PKDL. A total of 76 snip-skin samples collected from individuals with probable PKDL (clinical presentation and a positive rK39 rapid diagnostic test (RDT)) were assessed by microscopy, qPCR, and LAMP. An equal number of age and sex-matched healthy controls were included to determine the specificity of the LAMP assay. The LAMP assay with a Qiagen DNA extraction (Q-LAMP) showed a promising sensitivity of 72.37% (95% CI: 60.91–82.01%) for identifying the PKDL cases. LAMP assay sensitivity declined when the DNA was extracted using a boil-spin method. Q-qPCR showed 68.42% (56.75–78.61%) sensitivity, comparable to LAMP and with an excellent agreement, whereas the microscopy exhibited a weak sensitivity of 39.47% (28.44–51.35%). When microscopy and/or qPCR were considered the gold standard, Q-LAMP exhibited an elevated sensitivity of 89.7% (95% CI: 78.83–96.11%) for detection of PKDL cases and Bayesian latent class modeling substantiated the excellent sensitivity of the assay. All healthy controls were found to be negative. Notwithstanding the optimum efficiency of the LAMP assay towards the detection of PKDL cases, further optimization of the boil-spin method is warranted to permit remote use of the assay.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 icddr,b, Nutrition and Clinical Services Division, Dhaka, Bangladesh (GRID:grid.414142.6) (ISNI:0000 0004 0600 7174)
2 Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland (GRID:grid.452485.a) (ISNI:0000 0001 1507 3147)
3 Department of Tropical Disease Biology, Liverpool School of Tropical Medicine (LSTM), Liverpool, UK (GRID:grid.48004.38) (ISNI:0000 0004 1936 9764)
4 The University of Newcastle, School of Medicine and Public Health, Callaghan, Australia (GRID:grid.266842.c) (ISNI:0000 0000 8831 109X)
5 National Heart Foundation and Research Institute, Mirpur, Bangladesh (GRID:grid.414142.6)
6 Infectious Disease Hospital, Dhaka, Bangladesh (GRID:grid.414142.6)
7 Mymensingh Medical College and Hospital (MMCH), Infectious and Tropical Medicine Department, Mymensingh, Bangladesh (GRID:grid.416352.7) (ISNI:0000 0004 5932 2709)
8 Stanford University School of Medicine, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
9 HDT Bio, Seattle, USA (GRID:grid.168010.e)
10 Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland (GRID:grid.452485.a) (ISNI:0000 0001 1507 3147); Noguchi Memorial Institute for Medical Research, University of Ghana, Department of Parasitology, College of Health Sciences, Legon, Ghana (GRID:grid.462644.6) (ISNI:0000 0004 0452 2500)
11 Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland (GRID:grid.452485.a) (ISNI:0000 0001 1507 3147); National School of Public Health, CIBERINFEC, Instituto de Salud Carlos III ES, Madrid, Spain (GRID:grid.512889.f) (ISNI:0000 0004 1768 0241)